Tiziana Life Sciences (TSLA) Develops TZLS-50 to Treat COVID-19 Patients with at Risk of Respiratory Failure
Go back to Tiziana Life Sciences (TSLA) Develops TZLS-50 to Treat COVID-19 Patients with at Risk of Respiratory Failure| (NASDAQ: TLSA) | Delayed: 1.16 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $1.16 | 52 Week High | $ | |||
| Open | $1.16 | 52 Week Low | $ | |||
| Day High | $1.16 | P/E | N/A | |||
| Day Low | $1.16 | EPS | $ | |||
| Volume | 1,545 | |||||
